General Information of the Disease (ID: M6ADIS0162)
Name
Pre-eclampsia
ICD
ICD-11: JA24
Full List of Target Gene(s) of This m6A-centered Disease Response
Forkhead box protein O3 (FOXO3)
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [2]
Response Summary Global RNA m6A methylation and METTL14 expression were significantly increased in placental tissues obtained from patients with preeclampsia. Forkhead box protein O3 (FOXO3) inhibition effectively prevented the impairment of trophoblast proliferation and invasion, and diminished the induction of trophoblast autophagy and apoptosis in METTL14-overexpressing HTR-8/SVneo cells.
Responsed Disease Pre-eclampsia [ICD-11: JA24]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
Target Regulation Up regulation
Cell Process Cell autophagy
In-vitro Model HTR-8/SVneo Normal Homo sapiens CVCL_7162
HTR-8 Normal Homo sapiens CVCL_D728
Heat shock 70 kDa protein 1A (HSPA1A)
In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [3]
Response Summary Findings show that METTL3 and METTL14 were up-regulated in preeclampsia(PE). Heat shock 70 kDa protein 1A (HSPA1A) is involved in the pathophysiology of PE as its mRNA and protein expression is regulated by m6A modification.
Responsed Disease Pre-eclampsia [ICD-11: JA24]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
Target Regulation Up regulation
Pathway Response Wnt signaling pathway hsa04310
mTOR signaling pathway hsa04150
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene [3]
Response Summary Findings show that METTL3 and METTL14 were up-regulated in preeclampsia(PE). Heat shock 70 kDa protein 1A (HSPA1A) is involved in the pathophysiology of PE as its mRNA and protein expression is regulated by m6A modification.
Responsed Disease Pre-eclampsia [ICD-11: JA24]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
Target Regulation Up regulation
Pathway Response Wnt signaling pathway hsa04310
mTOR signaling pathway hsa04150
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 3 item(s) under this disease
Crosstalk ID: M6ACROT05657
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target Circ_SETD2
Epigenetic Regulator Circ_SETD2
Regulated Target hsa-miR-181a-5p
Crosstalk relationship m6A → ncRNA
Crosstalk ID: M6ACROT05658
m6A Regulator Fat mass and obesity-associated protein (FTO)
m6A Target Circ_SETD2
Epigenetic Regulator Circ_SETD2
Regulated Target hsa-miR-181a-5p
Crosstalk relationship m6A → ncRNA
Crosstalk ID: M6ACROT05738
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target HOXD antisense growth-associated long non-coding RNA (HAGLR)
Epigenetic Regulator HOXD antisense growth-associated long non-coding RNA (HAGLR)
Regulated Target MicroRNA 135a-1 (MIR135A1)
Crosstalk relationship m6A → ncRNA
References
Ref 1 Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87. doi: 10.1111/j.1365-2125.2004.02156.x.
Ref 2 Upregulation of METTL14 contributes to trophoblast dysfunction by elevating FOXO3a expression in an m(6)A-dependent manner. Placenta. 2022 Jun 24;124:18-27. doi: 10.1016/j.placenta.2022.05.008. Epub 2022 May 14.
Ref 3 Integrated analysis of the transcriptome-wide m6A methylome in preeclampsia and healthy control placentas. PeerJ. 2020 Sep 15;8:e9880. doi: 10.7717/peerj.9880. eCollection 2020.
Ref 4 ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Ref 5 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. doi: 10.2174/092986709789057635. Epub 2009 Sep 1.
Ref 6 US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
Ref 7 Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40. doi: 10.1038/nrd1718.